{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:02:09Z","timestamp":1789560129665,"version":"build-2803163510"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"DOI":"10.1186\/s12902-026-02538-x","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:43:03Z","timestamp":1789479783000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of orforglipron 12\u00a0mg versus orforglipron 36\u00a0mg maintenance dose among patients with obesity with or without diabetes: a systematic review and comprehensive meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8825-7772","authenticated-orcid":false,"given":"Mohamed Gamal","family":"Hegaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5341-4258","authenticated-orcid":false,"given":"Mohammad Yassin Al","family":"Aboud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4512-8565","authenticated-orcid":false,"given":"Abanoub I. I.","family":"Kamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Abdullah","family":"Naveed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar Gamal","family":"Elsayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6411-8086","authenticated-orcid":false,"given":"Aqsa Zoey","family":"Sorathia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"2538_CR1","unstructured":"World Obesity Federation. World obesity atlas 2025. https:\/\/data.worldobesity.org\/publications\/?cat=23 (2025, accessed 12 December 2025)."},{"issue":"Suppl 3","key":"2538_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/EP161365.GL","volume":"22","author":"WT Garvey","year":"2016","unstructured":"Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(Suppl 3):1\u2013203.","journal-title":"Endocr Pract"},{"issue":"Suppl 1","key":"2538_CR3","doi-asserted-by":"publisher","first-page":"S100","DOI":"10.2337\/dc21-S008","volume":"44","author":"American Diabetes Association","year":"2021","unstructured":"American Diabetes Association. 8. obesity management for the treatment of type 2 diabetes: standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S100\u201310.","journal-title":"Diabetes Care"},{"issue":"1","key":"2538_CR4","doi-asserted-by":"publisher","first-page":"107","DOI":"10.4158\/CS-2019-0472","volume":"26","author":"AJ Garber","year":"2020","unstructured":"Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm\u2009\u2013\u20092020 executive summary. Endocr Pract. 2020;26(1):107\u201339.","journal-title":"Endocr Pract"},{"issue":"Suppl 1","key":"2538_CR5","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.2337\/dc21-S009","volume":"44","author":"American Diabetes Association","year":"2021","unstructured":"American Diabetes Association. 9. pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S111\u201324.","journal-title":"Diabetes Care"},{"issue":"11","key":"2538_CR6","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989\u20131002.","journal-title":"N Engl J Med"},{"issue":"3","key":"2538_CR7","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/dom.13955","volume":"22","author":"M Husain","year":"2020","unstructured":"Husain M, Bain SC, Jeppesen OK, et al. Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk. Diabetes Obes Metab. 2020;22(3):442\u201351.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"2538_CR8","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/ijo.2011.158","volume":"36","author":"A Astrup","year":"2012","unstructured":"Astrup A, Carraro R, Finer N, et al. Safety, tolerability, and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond). 2012;36(6):843\u201354.","journal-title":"Int J Obes (Lond)"},{"issue":"3","key":"2538_CR9","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205\u201316.","journal-title":"N Engl J Med"},{"issue":"10403","key":"2538_CR10","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","volume":"402","author":"FK Knop","year":"2023","unstructured":"Knop FK, Aroda VR, do Vale RD, et al. Oral semaglutide 50\u00a0mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402(10403):705\u201319.","journal-title":"Lancet"},{"issue":"47","key":"2538_CR11","doi-asserted-by":"publisher","first-page":"29959","DOI":"10.1073\/pnas.2014879117","volume":"117","author":"T Kawai","year":"2020","unstructured":"Kawai T, Sun B, Yoshino H, et al. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist. Proc Natl Acad Sci U S A. 2020;117(47):29959\u201367.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2538_CR12","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.2147\/PPA.S463354","volume":"18","author":"JT Myers","year":"2024","unstructured":"Myers JT, Dam JV, Imran M, et al. Preference for a novel oral alternative to parenterally administered medications. Patient Prefer Adherence. 2024;18:1547\u201362.","journal-title":"Patient Prefer Adherence"},{"key":"2538_CR13","doi-asserted-by":"publisher","unstructured":"Hammad N, Ramadan AM, Nazmy A, et al. Efficacy and safety of oral GLP-1 RA Orforglipron on weight and glycemic control according to diabetes status: A systematic review and meta-analysis. Diabetes Technol Ther. Epub ahead of print 4 February 2026. https:\/\/doi.org\/10.1177\/15209156261420404.","DOI":"10.1177\/15209156261420404"},{"issue":"10534","key":"2538_CR14","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(26)00202-3","volume":"407","author":"J Rosenstock","year":"2026","unstructured":"Rosenstock J, Yabe D, Cox D, et al. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial. Lancet. 2026;407(10534):1147\u201360.","journal-title":"Lancet"},{"key":"2538_CR15","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"2538_CR16","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"2538_CR17","volume-title":"5 (RevMan 5) [computer program]. Version 5.4","author":"Review Manager","year":"2020","unstructured":"Review Manager. 5 (RevMan 5) [computer program]. Version 5.4. Copenhagen: The Cochrane Collaboration; 2020."},{"issue":"10522","key":"2538_CR18","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1016\/S0140-6736(25)02165-8","volume":"406","author":"DB Horn","year":"2026","unstructured":"Horn DB, Ryan DH, Kis SG, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. Lancet. 2026;406(10522):2927\u201344.","journal-title":"Lancet"},{"issue":"10400","key":"2538_CR19","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S0140-6736(23)01302-8","volume":"402","author":"JP Frias","year":"2023","unstructured":"Frias JP, Hsia S, Eyde S, et al. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet. 2023;402(10400):472\u201383.","journal-title":"Lancet"},{"issue":"11","key":"2538_CR20","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1056\/NEJMoa2505669","volume":"393","author":"J Rosenstock","year":"2025","unstructured":"Rosenstock J, Hsia S, Nevarez Ruiz L, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, in Early Type 2 Diabetes. N Engl J Med. 2025;393(11):1065\u201376.","journal-title":"N Engl J Med"},{"issue":"10","key":"2538_CR21","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJMoa2302392","volume":"389","author":"S Wharton","year":"2023","unstructured":"Wharton S, Blevins T, Connery L, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023;389(10):877\u201388.","journal-title":"N Engl J Med"},{"issue":"18","key":"2538_CR22","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1056\/NEJMoa2511774","volume":"393","author":"S Wharton","year":"2025","unstructured":"Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med. 2025;393(18):1796\u2013806.","journal-title":"N Engl J Med"},{"issue":"2","key":"2538_CR23","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/jdi.70157","volume":"17","author":"K Ohwaki","year":"2026","unstructured":"Ohwaki K, Nakamura C, Nasu R, et al. A phase 1 single and multiple ascending dose study of orforglipron in Japanese participants with type 2 diabetes. J Diabetes Investig. 2026;17(2):205\u201313.","journal-title":"J Diabetes Investig"},{"issue":"9","key":"2538_CR24","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1111\/dom.15150","volume":"25","author":"E Pratt","year":"2023","unstructured":"Pratt E, Ma X, Liu R, et al. Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes. Diabetes Obes Metab. 2023;25(9):2642\u20139.","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"2538_CR25","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1111\/dom.15184","volume":"25","author":"E Pratt","year":"2023","unstructured":"Pratt E, Ma X, Liu R, et al. Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants. Diabetes Obes Metab. 2023;25(9):2634\u201341.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"2538_CR26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.cmet.2016.06.009","volume":"24","author":"DJ Drucker","year":"2016","unstructured":"Drucker DJ. The cardiovascular biology of glucagon-like peptide-1. Cell Metab. 2016;24(1):15\u201330.","journal-title":"Cell Metab"},{"issue":"25 Suppl 2","key":"2538_CR27","first-page":"S102","volume":"129","author":"MD Jensen","year":"2014","unstructured":"Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology\/American Heart Association task force on practice guidelines and The Obesity Society. Circulation. 2014;129(25 Suppl 2):S102\u201338.","journal-title":"Circulation"},{"issue":"7","key":"2538_CR28","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.2337\/dc10-2415","volume":"34","author":"RR Wing","year":"2011","unstructured":"Wing RR, Lang W, Wadden TA, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34(7):1481\u20136.","journal-title":"Diabetes Care"},{"issue":"1","key":"2538_CR29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0\u00a0mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11\u201322.","journal-title":"N Engl J Med"},{"issue":"9","key":"2538_CR30","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/S2213-8587(19)30084-1","volume":"7","author":"IJ Neeland","year":"2019","unstructured":"Neeland IJ, Ross R, Despr\u00e9s JP, et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol. 2019;7(9):715\u201325.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"2538_CR31","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1172\/JCI81507","volume":"125","author":"U Smith","year":"2015","unstructured":"Smith U. Abdominal obesity: a marker of ectopic fat accumulation. J Clin Invest. 2015;125(5):1790\u20132.","journal-title":"J Clin Invest"},{"issue":"6","key":"2538_CR32","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503\u201315.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"2538_CR33","doi-asserted-by":"publisher","first-page":"S83","DOI":"10.2337\/dc22-S006","volume":"45","author":"American Diabetes Association Professional Practice Committee","year":"2022","unstructured":"American Diabetes Association Professional Practice Committee. 6. Glycemic targets: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S83\u201396.","journal-title":"Diabetes Care"},{"issue":"10192","key":"2538_CR34","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","volume":"394","author":"R Pratley","year":"2019","unstructured":"Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019;394(10192):39\u201350.","journal-title":"Lancet"},{"issue":"11","key":"2538_CR35","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2337\/dci22-0034","volume":"45","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753\u201386.","journal-title":"Diabetes Care"},{"issue":"5","key":"2538_CR36","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s10557-013-6463-z","volume":"27","author":"Y Dai","year":"2013","unstructured":"Dai Y, Mehta JL, Chen M. Glucagon-like peptide-1 receptor agonist liraglutide inhibits endothelin-1 in endothelial cells by repressing nuclear factor-kappa B activation. Cardiovasc Drugs Ther. 2013;27(5):371\u201380.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"10","key":"2538_CR37","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","volume":"7","author":"SL Kristensen","year":"2019","unstructured":"Kristensen SL, R\u00f8rth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7(10):776\u201385.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"2538_CR38","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.diabres.2015.07.015","volume":"110","author":"F Sun","year":"2015","unstructured":"Sun F, Wu S, Guo S, et al. Impact of GLP-1 receptor agonists on blood pressure, heart rate, and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis. Diabetes Res Clin Pract. 2015;110(1):26\u201337.","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"2538_CR39","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/apt.12149","volume":"37","author":"MJ Armstrong","year":"2013","unstructured":"Armstrong MJ, Houlihan DD, Rowe IA, et al. Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program. Aliment Pharmacol Ther. 2013;37(2):234\u201342.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"2538_CR40","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322.","journal-title":"N Engl J Med"},{"issue":"19","key":"2538_CR41","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344.","journal-title":"N Engl J Med"},{"issue":"10193","key":"2538_CR42","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121\u201330.","journal-title":"Lancet"},{"issue":"4","key":"2538_CR43","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1161\/HYPERTENSIONAHA.114.03062","volume":"64","author":"KC Ferdinand","year":"2014","unstructured":"Ferdinand KC, White WB, Calhoun DA, et al. Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Hypertension. 2014;64(4):731\u20137.","journal-title":"Hypertension"},{"issue":"9","key":"2538_CR44","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1056\/NEJMp1314078","volume":"370","author":"AG Egan","year":"2014","unstructured":"Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs\u2013FDA and EMA assessment. N Engl J Med. 2014;370(9):794\u20137.","journal-title":"N Engl J Med"},{"issue":"2","key":"2538_CR45","first-page":"407","volume":"102","author":"JM Petit","year":"2017","unstructured":"Petit JM, Cercueil JP, Loffroy R, et al. Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes: the Lira-NAFLD study. J Clin Endocrinol Metab. 2017;102(2):407\u201315.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2538_CR46","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.diabet.2019.12.007","volume":"46","author":"A Mantovani","year":"2020","unstructured":"Mantovani A, Byrne CD, Scorletti E, et al. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials. Diabetes Metab. 2020;46(6):427\u201341.","journal-title":"Diabetes Metab"},{"issue":"2","key":"2538_CR47","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1210\/jc.2014-3415","volume":"100","author":"CM Apovian","year":"2015","unstructured":"Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342\u201362.","journal-title":"J Clin Endocrinol Metab"},{"issue":"22","key":"2538_CR48","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1001\/jama.2016.7602","volume":"315","author":"R Khera","year":"2016","unstructured":"Khera R, Murad MH, Chandar AK, et al. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA. 2016;315(22):2424\u201334.","journal-title":"JAMA"},{"key":"2538_CR49","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.2147\/PPA.S106821","volume":"10","author":"WH Polonsky","year":"2016","unstructured":"Polonsky WH, Henry RR. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Prefer Adherence. 2016;10:1299\u2013307.","journal-title":"Patient Prefer Adherence"},{"issue":"14","key":"2538_CR50","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","volume":"325","author":"D Rubino","year":"2021","unstructured":"Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414\u201325.","journal-title":"JAMA"},{"issue":"7","key":"2538_CR51","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1210\/clinem\/dgab091","volume":"106","author":"K Kheniser","year":"2021","unstructured":"Kheniser K, Saxon DR, Kashyap SR. Long-term weight loss strategies for obesity. J Clin Endocrinol Metab. 2021;106(7):1854\u201366.","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"2538_CR52","doi-asserted-by":"publisher","first-page":"S128","DOI":"10.2337\/dc23-S008","volume":"46","author":"NA ElSayed","year":"2023","unstructured":"ElSayed NA, Aleppo G, Aroda VR, et al. 8. obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S128\u201339.","journal-title":"Diabetes Care"},{"issue":"5","key":"2538_CR53","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1001\/jama.2025.24288","volume":"335","author":"F Celletti","year":"2026","unstructured":"Celletti F, Farrar J, De Regil L. World \u0627ealth Organization guideline on the use and indications of glucagon-like peptide-1 therapies for the treatment of obesity in adults. JAMA. 2026;335(5):434\u20138.","journal-title":"JAMA"},{"issue":"1","key":"2538_CR54","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.mcna.2017.08.012","volume":"102","author":"KD Hall","year":"2018","unstructured":"Hall KD, Kahan S. Maintenance of lost weight and long-term management of obesity. Med Clin North Am. 2018;102(1):183\u201397.","journal-title":"Med Clin North Am"},{"issue":"7","key":"2538_CR55","doi-asserted-by":"publisher","first-page":"e99682","DOI":"10.1371\/journal.pone.0099682","volume":"9","author":"G Salanti","year":"2014","unstructured":"Salanti G, Del Giovane C, Chaimani A, et al. Evaluating the quality of evidence from a network meta-analysis. PLoS ONE. 2014;9(7):e99682.","journal-title":"PLoS ONE"},{"issue":"2","key":"2538_CR56","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJMoa1212914","volume":"369","author":"AHEADR Look","year":"2013","unstructured":"Look AHEADR, Group, Wing RR, Bolin P, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145\u201354.","journal-title":"N Engl J Med"},{"issue":"17","key":"2538_CR57","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","volume":"139","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation. 2019;139(17):2022\u201331.","journal-title":"Circulation"},{"issue":"10434","key":"2538_CR58","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1016\/S0140-6736(24)00351-9","volume":"403","author":"Q Shi","year":"2024","unstructured":"Shi Q, Wang Y, Hao Q, et al. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. Lancet. 2024;403(10434):e31. https:\/\/doi.org\/10.1016\/S0140-6736(24)00351-9.","journal-title":"Lancet"},{"issue":"1","key":"2538_CR59","doi-asserted-by":"publisher","first-page":"10","DOI":"10.17925\/EE.2022.18.1.10","volume":"18","author":"S Kaneko","year":"2022","unstructured":"Kaneko S, Tirzepatide. A novel, once-weekly dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes. touchREV Endocrinol. 2022;18(1):10\u20139.","journal-title":"touchREV Endocrinol"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-026-02538-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-026-02538-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-026-02538-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:03:03Z","timestamp":1789556583000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12902-026-02538-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2538"],"URL":"https:\/\/doi.org\/10.1186\/s12902-026-02538-x","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"assertion":[{"value":"18 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No humans participate in this study, and informed consent is not required.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"273"}}